Skip to content

Public FDA record

Z-0031-2026: Phasitron 5, IPV In-Line Valve, (Intrapulmonary Percussive Ventilation) REF: P5-TEE-20 (pack of 20)/ P5-T

Recall record Z-0031-2026 for Percussionaire Corporation. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0031-2026
Company in FDA record
Percussionaire Corporation
FDA classification date
Oct 14, 2025
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class I

Reason stated in the source

IFU update; in-line valve, with pressure relief seal may leak when used with ventilator; don't use in neonates/infants, with target tidal volumes less-than50mL or less-than10kg- at high risk of cardiopulmonary/neurological compromise due to unrecognized hypoventilation, updates for continued use in others before design update; leak may cause respiratory acidosis, hypoxemia, or respiratory failure.

Source facts

Action
On 9/17/2025, correction notices were emailed to customers who were informed of future design update and current instructions for use update, and advised: If adequate exhaled tidal volumes cannot be achieved with the In-Line Valve in place, consider removing the IN-Line Valve from the circuit when IPV therapy is not being delivered or choose a different treatment configuration (e.g., direct to artificial airway). Insufficient exhaled tidal volumes may lead to hypoventilation. At initial placement of the In-Line Valve in the inspiratory limb: (either at the patient wye or on the dry side of the humidifier) Allow the ventilator to complete two or more cycles and adjust settings, if necessary, to compensate for any potential leaks and to ensure exhaled tidal volumes are adequate. At completion of IPV treatment when performed with In-Line Valve: 1) Close pressure relief adjustment valve and turn off IPV device in quick succession. 2) Restore ventilator settings noted before treatment and reassess the patient. 3) Allow the ventilator to complete two or more cycles and adjust settings, if necessary, to ensure exhaled tidal volumes are adequate. Warning: The In-Line Valve should not be used in neonates and infants who are at high risk of cardiopulmonary or neurological compromise due to unrecognized hypoventilation. Customers asked to do the following: 1) Print and post updated instructions for use throughout your facility. 2) Communicate and train primary users of IPV therapy. 3) Review instructional protocols and update as needed to conform to the updated instructions. 4) Re-label current product by placing the sticker provided by firm on each individual In-Line Valve bag in stock below the current product label. Distributors were asked to forward the notice to their customers. Questions can be directed to firm via email at: FSCA@sentec.com
Initiated
2025-09-17
Root cause
Device Design
Distribution
Worldwide distribution. US nationwide, Russia, Japan, Switzerland, Canada, Qatar, Chile, South Africa, United Kingdom, Israel, Turkey, and UAE
Recall number
Z-0031-2026
Recall status
Open, Classified
CDRH record ID
215428
FDA classified
2025-10-14
Recall event number
97374

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗